Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Optiscan Imaging Limited ( (AU:OIL) ) is now available.
Optiscan Imaging Ltd has successfully raised $17.75 million through a fully underwritten pro-rata renounceable entitlement offer, issuing over 208 million new shares. This capital will fund Optiscan’s strategic transformation into a medical device manufacturer and digital healthcare solution provider, enhancing its market positioning and potentially benefiting stakeholders by expanding its product offerings and market reach.
More about Optiscan Imaging Limited
Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company specializing in digital pathology and precision surgery solutions. They develop and manufacture miniaturized digital endomicroscopes with high spatial resolution for live optical biopsy applications in life sciences, diagnostics, and surgery. Their technology supports real-time, non-destructive, 3D, in-vivo imaging at the single-cell level, enhancing disease detection and treatment outcomes. Optiscan is positioned to serve the growing digital health market, including robotic surgery, by bridging the gap between surgery and pathology.
Average Trading Volume: 123,793
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$88.75M
For a thorough assessment of OIL stock, go to TipRanks’ Stock Analysis page.